Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04YHG
|
|||
| Former ID |
DIB012378
|
|||
| Drug Name |
ErepoXen
|
|||
| Indication | Anemia [ICD-11: 3A00-3A9Z; ICD-9: 280-285] | Phase 3 | [1] | |
| Company |
Lipoxen plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Erythropoietin Receptor (EPOR) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| PI3K-Akt signaling pathway | ||||
| Jak-STAT signaling pathway | ||||
| Hematopoietic cell lineage | ||||
| NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
| Pathway Interaction Database | Signaling events mediated by Stem cell factor receptor (c-Kit) | |||
| EPO signaling pathway | ||||
| WikiPathways | EPO Receptor Signaling | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033828) | |||
| REF 2 | Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.